Two months after Intercell CEO Gerd Zettlmeissl insisted that the decision to halt patient recruitment for a Phase II/III trial of its experimental vaccine V710 did not signal the end of the program--and a month after Zettlmeissl unceremoniously departed from the helm--the biotech and its partner Merck announced that they are shuttering the troubled study. After a series of heavy blows over the past year, investors responded by carving another chunk out of Intercell's stock price.

Read the full story at Reuters